DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Beta Thalassemia Treatment - Insights Into the Challenges & Solutions Visit Post
2 Most Promising Oncological Drugs Expected to Launch in 2022 Visit Post
3 Sky Medical’s Geko™ device; Fist Assist Devices obtains Breakthrough Device designation; Edwards obtains FDA approval; BD launched instrument for testing; GE acquires BK Medical; Zynex’ CM-1500; Foldax’s TRIA biopolymer heart valve Visit Post
4 Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021 Visit Post
5 Major Highlights of Follicular Lymphoma (FL) in ASH 2021 Visit Post
6 Pfizer to acquire Arena Pharma; Takeda's 'Wave 2' multiple myeloma med data; Novartis's next-gen CAR-Ts clinical data; Roche unveils Avenio system Visit Post
7 Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021 Visit Post
8 Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!! Visit Post
9 Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M Visit Post
10 The Evolved Gene Therapy for Hemophilia Visit Post
11 Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding Visit Post
12 An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1) Visit Post
13 von Willebrand disease (VWD) – Misdiagnosis Still Prevalent! Visit Post
14 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
15 AstraZeneca's Ultomiris; HebaBiz's Siroquine; Pfizer's XELJANZ; Bristol Myers Squibb's Opdivo; and Masimo's PVi Visit Post
16 Fecal Incontinence Therapeutics Market Surges with Innovative Therapies in the Pipeline Visit Post
17 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
18 Wearable Devices: Weighing the Potential Benefits and Pitfalls of the Innovative Wearable Products Visit Post
19 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
20 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
21 Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M Visit Post
22 Cidara Therapeutics and J&J’s USD 780M Deal; FDA’s Approval to Supernus’s ADHD drug; Rain Therapeutics USD 100M IPO; NMPA Approval to Antengene’s ATG-019 IND Application Visit Post
23 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
24 Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels Visit Post
25 Bleeding Disorders: How Key Companies Are Shaping The Bleeding Disorders Therapeutics Market? Visit Post
26 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
27 A Royal Disease: Hemophilia Visit Post
28 Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Visit Post
29 Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities Visit Post
30 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
31 Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Visit Post
32 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
33 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
34 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
35 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
36 Overcoming the prevailing unmet needs in Beta-Thalassemia Market Visit Post
37 Vir's drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines Visit Post
38 Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs Visit Post
39 Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast Visit Post
40 Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine Visit Post
41 GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3 Visit Post
42 Wave Life Sciences stocks implode; Amarin’s VASCEPA approval; GSK seeks approval Visit Post
43 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
44 Novel treatment approval promises a better future for Sickle cell disease patients Visit Post
45 How Gene therapy is changing the Beta-thalassemia Treatment outlook? Visit Post
46 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
47 GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion Visit Post
48 Beta-Thalassemia Pharmacological Therapies Visit Post
49 FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit Visit Post
50 Themis Bioscience collaborates with Merck; Oncorus raises USD 80 M; GSK files for Japanese approval of anaemia drug Visit Post
51 Myelofibrosis Therapeutics Market Visit Post
52 World Sickle Cell Day Visit Post
53 World Blood Donor Day Visit Post
54 World Thalassemia Day Visit Post
55 World Haemophilia Day Visit Post
56 Multiple Myeloma Day Visit Post
57 The changing landscape of Multiple Myeloma therapies market Visit Post
58 The Business Cocktail Visit Post
59 BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M Visit Post
60 Notizia Visit Post
61 Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO Visit Post
62 COMMERCIAL AND OTHERS Visit Post
63 Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray Visit Post
64 Companion Diagnostics Visit Post
65 Snippet Visit Post
66 Biologic Parallel – A Perky Future Ahead Visit Post
67 Notizia Visit Post
68 Key Clinical Outcomes- 30/07/2018 Visit Post
69 Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod Visit Post
70 Hemophilia A- Market Scenario Visit Post
71 Novartis’s Entresto; AZ, J&J and Lilly sharply cut death rates; CAR-T drugs worth; FDA warns Visit Post
72 Business Cocktail Visit Post
73 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
74 Hemophilia - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
75 A Glimpse of the Anticoagulants Therapy Market; Major Players Visit Post
76 Anticoagulants Market A Big Boom Visit Post
77 DelveInsight’s Hematological disorders based Gene Therapy Reports Visit Post
78 Global Hemophilia Market Visit Post